Stock Analysis on Net

Illumina Inc. (NASDAQ:ILMN)

This company was transferred to the archive: financial data is no longer updated!

Analysis of Short-term (Operating) Activity Ratios

Microsoft Excel LibreOffice Calc

Short-term Activity Ratios (Summary)

Illumina Inc., short-term (operating) activity ratios

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Dec 29, 2019 Dec 30, 2018 Dec 31, 2017 Dec 31, 2016
Turnover Ratios
Inventory turnover 2.78 3.00 2.68 2.78 2.44
Receivables turnover 6.65 6.18 6.48 6.70 6.29
Payables turnover 5.40 7.22 5.61 5.79 5.31
Working capital turnover 1.00 0.94 1.24 1.23 1.49
Average No. Days
Average inventory processing period 131 122 136 131 150
Add: Average receivable collection period 55 59 56 55 58
Operating cycle 186 181 192 186 208
Less: Average payables payment period 68 51 65 63 69
Cash conversion cycle 118 130 127 123 139

Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).

Short-term activity ratio Description The company
Inventory turnover An activity ratio calculated as cost of goods sold divided by inventory. Illumina Inc. inventory turnover ratio improved from 2018 to 2019 but then slightly deteriorated from 2019 to 2020 not reaching 2018 level.
Receivables turnover An activity ratio equal to revenue divided by receivables. Illumina Inc. receivables turnover ratio deteriorated from 2018 to 2019 but then improved from 2019 to 2020 exceeding 2018 level.
Payables turnover An activity ratio calculated as cost of goods sold divided by payables. Illumina Inc. payables turnover ratio increased from 2018 to 2019 but then decreased significantly from 2019 to 2020.
Working capital turnover An activity ratio calculated as revenue divided by working capital. Illumina Inc. working capital turnover ratio deteriorated from 2018 to 2019 but then slightly improved from 2019 to 2020.

Short-term activity ratio Description The company
Average inventory processing period An activity ratio equal to the number of days in the period divided by inventory turnover over the period. Illumina Inc. number of days of inventory outstanding improved from 2018 to 2019 but then slightly deteriorated from 2019 to 2020 not reaching 2018 level.
Average receivable collection period An activity ratio equal to the number of days in the period divided by receivables turnover. Illumina Inc. number of days of receivables outstanding deteriorated from 2018 to 2019 but then improved from 2019 to 2020 exceeding 2018 level.
Operating cycle Equal to average inventory processing period plus average receivables collection period. Illumina Inc. operating cycle improved from 2018 to 2019 but then slightly deteriorated from 2019 to 2020.
Average payables payment period An estimate of the average number of days it takes a company to pay its suppliers; equal to the number of days in the period divided by payables turnover ratio for the period. Illumina Inc. number of days of payables outstanding decreased from 2018 to 2019 but then increased from 2019 to 2020 exceeding 2018 level.
Cash conversion cycle A financial metric that measures the length of time required for a company to convert cash invested in its operations to cash received as a result of its operations; equal to average inventory processing period plus average receivables collection period minus average payables payment period. Illumina Inc. cash conversion cycle deteriorated from 2018 to 2019 but then improved from 2019 to 2020 exceeding 2018 level.

Inventory Turnover

Illumina Inc., inventory turnover calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Dec 29, 2019 Dec 30, 2018 Dec 31, 2017 Dec 31, 2016
Selected Financial Data (US$ in millions)
Cost of revenue 1,036  1,076  1,033  926  732 
Inventory 372  359  386  333  300 
Short-term Activity Ratio
Inventory turnover1 2.78 3.00 2.68 2.78 2.44
Benchmarks
Inventory Turnover, Competitors2
AbbVie Inc. 4.65 4.10 4.81 4.39 4.04
Amgen Inc. 1.58 1.22 1.39 1.44 1.52
Eli Lilly & Co. 1.38 1.48 1.56 1.36 1.59
Gilead Sciences Inc. 2.72 5.07 5.96 5.46 2.68
Johnson & Johnson 3.04 3.05 3.15 2.89 2.66
Merck & Co. Inc. 2.45 2.36 2.48 2.51 2.85
Moderna Inc. 0.17
Pfizer Inc. 1.08 1.23 1.50 1.48 1.82
Regeneron Pharmaceuticals Inc. 0.26 0.26 0.16 0.28 0.49
Thermo Fisher Scientific Inc. 4.02 4.22 4.49 3.86 4.48
Zoetis Inc. 1.26 1.41 1.37 1.24 1.11
Inventory Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences 2.33 2.30 2.48 2.33
Inventory Turnover, Industry
Health Care 7.47 7.59 7.41 7.31

Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).

1 2020 Calculation
Inventory turnover = Cost of revenue ÷ Inventory
= 1,036 ÷ 372 = 2.78

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Inventory turnover An activity ratio calculated as cost of goods sold divided by inventory. Illumina Inc. inventory turnover ratio improved from 2018 to 2019 but then slightly deteriorated from 2019 to 2020 not reaching 2018 level.

Receivables Turnover

Illumina Inc., receivables turnover calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Dec 29, 2019 Dec 30, 2018 Dec 31, 2017 Dec 31, 2016
Selected Financial Data (US$ in millions)
Revenue 3,239  3,543  3,333  2,752  2,398 
Accounts receivable, net 487  573  514  411  381 
Short-term Activity Ratio
Receivables turnover1 6.65 6.18 6.48 6.70 6.29
Benchmarks
Receivables Turnover, Competitors2
AbbVie Inc. 5.19 6.13 6.08 5.55 5.39
Amgen Inc. 5.36 5.47 6.29 6.73 6.92
Eli Lilly & Co. 4.18 4.91 4.68 5.03 5.27
Gilead Sciences Inc. 4.98 6.18 6.52 6.66 6.64
Johnson & Johnson 6.08 5.67 5.79 5.67 6.14
Merck & Co. Inc. 6.11 6.91 5.98 5.84 5.67
Moderna Inc. 0.14 0.00 0.00
Pfizer Inc. 5.28 5.93 6.68 6.39 6.42
Regeneron Pharmaceuticals Inc. 1.79 2.30 2.38 2.42 2.49
Thermo Fisher Scientific Inc. 5.61 5.87 5.89 5.39 5.99
Zoetis Inc. 6.59 5.76 5.62 5.32 5.35
Receivables Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences 5.19 5.75 5.84 5.75
Receivables Turnover, Industry
Health Care 8.05 8.31 8.04 8.26

Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).

1 2020 Calculation
Receivables turnover = Revenue ÷ Accounts receivable, net
= 3,239 ÷ 487 = 6.65

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Receivables turnover An activity ratio equal to revenue divided by receivables. Illumina Inc. receivables turnover ratio deteriorated from 2018 to 2019 but then improved from 2019 to 2020 exceeding 2018 level.

Payables Turnover

Illumina Inc., payables turnover calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Dec 29, 2019 Dec 30, 2018 Dec 31, 2017 Dec 31, 2016
Selected Financial Data (US$ in millions)
Cost of revenue 1,036  1,076  1,033  926  732 
Accounts payable 192  149  184  160  138 
Short-term Activity Ratio
Payables turnover1 5.40 7.22 5.61 5.79 5.31
Benchmarks
Payables Turnover, Competitors2
AbbVie Inc. 6.76 5.12 4.99 4.78 4.15
Amgen Inc. 4.33 3.18 3.40 3.01 4.54
Eli Lilly & Co. 3.41 3.36 4.55 4.30 4.19
Gilead Sciences Inc. 5.42 6.56 6.14 5.37 3.53
Johnson & Johnson 2.99 3.23 3.59 3.47 3.13
Merck & Co. Inc. 3.37 3.78 4.07 4.12 4.95
Moderna Inc. 0.43 0.00 0.00
Pfizer Inc. 2.02 2.42 2.41 2.41 2.72
Regeneron Pharmaceuticals Inc. 1.03 0.87 0.82 1.14 1.44
Thermo Fisher Scientific Inc. 7.45 7.40 8.36 8.03 10.69
Zoetis Inc. 4.50 6.62 6.11 6.80 6.29
Payables Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences 3.72 3.72 4.00 3.84
Payables Turnover, Industry
Health Care 7.23 7.60 7.41 7.25

Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).

1 2020 Calculation
Payables turnover = Cost of revenue ÷ Accounts payable
= 1,036 ÷ 192 = 5.40

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Payables turnover An activity ratio calculated as cost of goods sold divided by payables. Illumina Inc. payables turnover ratio increased from 2018 to 2019 but then decreased significantly from 2019 to 2020.

Working Capital Turnover

Illumina Inc., working capital turnover calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Dec 29, 2019 Dec 30, 2018 Dec 31, 2017 Dec 31, 2016
Selected Financial Data (US$ in millions)
Current assets 4,483  4,451  4,490  2,980  2,318 
Less: Current liabilities 1,244  665  1,804  746  705 
Working capital 3,239  3,786  2,686  2,234  1,613 
 
Revenue 3,239  3,543  3,333  2,752  2,398 
Short-term Activity Ratio
Working capital turnover1 1.00 0.94 1.24 1.23 1.49
Benchmarks
Working Capital Turnover, Competitors2
AbbVie Inc. 0.98 6.16 4.00
Amgen Inc. 2.55 3.96 0.93 0.54 0.63
Eli Lilly & Co. 4.93 11.54 2.84 4.90 5.16
Gilead Sciences Inc. 5.30 1.08 0.86 1.27 2.67
Johnson & Johnson 9.44 8.81 5.51 6.09 1.86
Merck & Co. Inc. 109.83 8.90 11.53 6.52 2.97
Moderna Inc. 0.10 0.00 0.00
Pfizer Inc. 4.58 2.97 4.90 6.74
Regeneron Pharmaceuticals Inc. 0.79 0.86 0.82 1.16 1.72
Thermo Fisher Scientific Inc. 2.76 4.48 5.44 8.82 8.48
Zoetis Inc. 1.50 2.13 1.83 1.70 2.15
Working Capital Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences 5.80 3.63 2.89 2.76
Working Capital Turnover, Industry
Health Care 10.55 7.14 6.49 5.44

Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).

1 2020 Calculation
Working capital turnover = Revenue ÷ Working capital
= 3,239 ÷ 3,239 = 1.00

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Working capital turnover An activity ratio calculated as revenue divided by working capital. Illumina Inc. working capital turnover ratio deteriorated from 2018 to 2019 but then slightly improved from 2019 to 2020.

Average Inventory Processing Period

Illumina Inc., average inventory processing period calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Dec 29, 2019 Dec 30, 2018 Dec 31, 2017 Dec 31, 2016
Selected Financial Data
Inventory turnover 2.78 3.00 2.68 2.78 2.44
Short-term Activity Ratio (no. days)
Average inventory processing period1 131 122 136 131 150
Benchmarks (no. days)
Average Inventory Processing Period, Competitors2
AbbVie Inc. 79 89 76 83 90
Amgen Inc. 231 300 262 254 241
Eli Lilly & Co. 265 247 233 268 230
Gilead Sciences Inc. 134 72 61 67 136
Johnson & Johnson 120 119 116 126 137
Merck & Co. Inc. 149 155 147 146 128
Moderna Inc. 2,141
Pfizer Inc. 338 296 244 246 201
Regeneron Pharmaceuticals Inc. 1,422 1,426 2,334 1,309 749
Thermo Fisher Scientific Inc. 91 87 81 95 82
Zoetis Inc. 289 258 266 293 329
Average Inventory Processing Period, Sector
Pharmaceuticals, Biotechnology & Life Sciences 157 159 147 157
Average Inventory Processing Period, Industry
Health Care 49 48 49 50

Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).

1 2020 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 2.78 = 131

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Average inventory processing period An activity ratio equal to the number of days in the period divided by inventory turnover over the period. Illumina Inc. number of days of inventory outstanding improved from 2018 to 2019 but then slightly deteriorated from 2019 to 2020 not reaching 2018 level.

Average Receivable Collection Period

Illumina Inc., average receivable collection period calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Dec 29, 2019 Dec 30, 2018 Dec 31, 2017 Dec 31, 2016
Selected Financial Data
Receivables turnover 6.65 6.18 6.48 6.70 6.29
Short-term Activity Ratio (no. days)
Average receivable collection period1 55 59 56 55 58
Benchmarks (no. days)
Average Receivable Collection Period, Competitors2
AbbVie Inc. 70 60 60 66 68
Amgen Inc. 68 67 58 54 53
Eli Lilly & Co. 87 74 78 73 69
Gilead Sciences Inc. 73 59 56 55 55
Johnson & Johnson 60 64 63 64 59
Merck & Co. Inc. 60 53 61 63 64
Moderna Inc. 2,539
Pfizer Inc. 69 62 55 57 57
Regeneron Pharmaceuticals Inc. 204 159 153 151 147
Thermo Fisher Scientific Inc. 65 62 62 68 61
Zoetis Inc. 55 63 65 69 68
Average Receivable Collection Period, Sector
Pharmaceuticals, Biotechnology & Life Sciences 70 63 62 63
Average Receivable Collection Period, Industry
Health Care 45 44 45 44

Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).

1 2020 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 6.65 = 55

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Average receivable collection period An activity ratio equal to the number of days in the period divided by receivables turnover. Illumina Inc. number of days of receivables outstanding deteriorated from 2018 to 2019 but then improved from 2019 to 2020 exceeding 2018 level.

Operating Cycle

Illumina Inc., operating cycle calculation, comparison to benchmarks

No. days

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Dec 29, 2019 Dec 30, 2018 Dec 31, 2017 Dec 31, 2016
Selected Financial Data
Average inventory processing period 131 122 136 131 150
Average receivable collection period 55 59 56 55 58
Short-term Activity Ratio
Operating cycle1 186 181 192 186 208
Benchmarks
Operating Cycle, Competitors2
AbbVie Inc. 149 149 136 149 158
Amgen Inc. 299 367 320 308 294
Eli Lilly & Co. 352 321 311 341 299
Gilead Sciences Inc. 207 131 117 122 191
Johnson & Johnson 180 183 179 190 196
Merck & Co. Inc. 209 208 208 209 192
Moderna Inc. 4,680
Pfizer Inc. 407 358 299 303 258
Regeneron Pharmaceuticals Inc. 1,626 1,585 2,487 1,460 896
Thermo Fisher Scientific Inc. 156 149 143 163 143
Zoetis Inc. 344 321 331 362 397
Operating Cycle, Sector
Pharmaceuticals, Biotechnology & Life Sciences 227 222 209 220
Operating Cycle, Industry
Health Care 94 92 94 94

Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).

1 2020 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 131 + 55 = 186

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Operating cycle Equal to average inventory processing period plus average receivables collection period. Illumina Inc. operating cycle improved from 2018 to 2019 but then slightly deteriorated from 2019 to 2020.

Average Payables Payment Period

Illumina Inc., average payables payment period calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Dec 29, 2019 Dec 30, 2018 Dec 31, 2017 Dec 31, 2016
Selected Financial Data
Payables turnover 5.40 7.22 5.61 5.79 5.31
Short-term Activity Ratio (no. days)
Average payables payment period1 68 51 65 63 69
Benchmarks (no. days)
Average Payables Payment Period, Competitors2
AbbVie Inc. 54 71 73 76 88
Amgen Inc. 84 115 107 121 80
Eli Lilly & Co. 107 109 80 85 87
Gilead Sciences Inc. 67 56 59 68 103
Johnson & Johnson 122 113 102 105 116
Merck & Co. Inc. 108 97 90 89 74
Moderna Inc. 845
Pfizer Inc. 181 151 152 151 134
Regeneron Pharmaceuticals Inc. 353 421 442 321 253
Thermo Fisher Scientific Inc. 49 49 44 45 34
Zoetis Inc. 81 55 60 54 58
Average Payables Payment Period, Sector
Pharmaceuticals, Biotechnology & Life Sciences 98 98 91 95
Average Payables Payment Period, Industry
Health Care 50 48 49 50

Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).

1 2020 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 5.40 = 68

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Average payables payment period An estimate of the average number of days it takes a company to pay its suppliers; equal to the number of days in the period divided by payables turnover ratio for the period. Illumina Inc. number of days of payables outstanding decreased from 2018 to 2019 but then increased from 2019 to 2020 exceeding 2018 level.

Cash Conversion Cycle

Illumina Inc., cash conversion cycle calculation, comparison to benchmarks

No. days

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Dec 29, 2019 Dec 30, 2018 Dec 31, 2017 Dec 31, 2016
Selected Financial Data
Average inventory processing period 131 122 136 131 150
Average receivable collection period 55 59 56 55 58
Average payables payment period 68 51 65 63 69
Short-term Activity Ratio
Cash conversion cycle1 118 130 127 123 139
Benchmarks
Cash Conversion Cycle, Competitors2
AbbVie Inc. 95 78 63 73 70
Amgen Inc. 215 252 213 187 214
Eli Lilly & Co. 245 212 231 256 212
Gilead Sciences Inc. 140 75 58 54 88
Johnson & Johnson 58 70 77 85 80
Merck & Co. Inc. 101 111 118 120 118
Moderna Inc. 3,835
Pfizer Inc. 226 207 147 152 124
Regeneron Pharmaceuticals Inc. 1,273 1,164 2,045 1,139 643
Thermo Fisher Scientific Inc. 107 100 99 118 109
Zoetis Inc. 263 266 271 308 339
Cash Conversion Cycle, Sector
Pharmaceuticals, Biotechnology & Life Sciences 129 124 118 125
Cash Conversion Cycle, Industry
Health Care 44 44 45 44

Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).

1 2020 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= 131 + 5568 = 118

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Cash conversion cycle A financial metric that measures the length of time required for a company to convert cash invested in its operations to cash received as a result of its operations; equal to average inventory processing period plus average receivables collection period minus average payables payment period. Illumina Inc. cash conversion cycle deteriorated from 2018 to 2019 but then improved from 2019 to 2020 exceeding 2018 level.